162148-16-5

Basic information

• Product Name: pidotiMod iMpurity E
• Synonyms: pidotiMod iMpurity E;[S-(R*,R*)]-3-[(5-Oxo-2-pyrrolidinyl)carbonyl]-4-thiazolidinecarboxylic acid;Pidotimod Impurity 3;(S)-3-((S)-5-oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic acid
• CAS NO: 162148-16-5
• Molecular Formula: C9H12N2O4S
• Molecular Weight: 244.26758
• Mol File: 162148-16-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: pidotiMod iMpurity E(CAS DataBase Reference)
• NIST Chemistry Reference: pidotiMod iMpurity E(162148-16-5)
• EPA Substance Registry System: pidotiMod iMpurity E(162148-16-5)

Safety Data

• Hazardous Substances Data: 162148-16-5(Hazardous Substances Data)

Usage

Uses

4S-Pidotimod is a Pidotimod enantiomer and impurity with pharmacological properties.

Upstream product

• 28990-85-4 pentachlorophenyl ester of L-pyroglutamic acid 
• 34592-47-7 L-thioproline 
• 98-79-3 L-Pyroglutamic acid 
• 4042-36-8 D-pyrrolidone-5-carboxylic acid 
• 50654-95-0 pentachlorophenyl ester of D-pyroglutamic acid 
• 444-27-9 L-thiaproline 
• 135124-63-9 ethyl-(R)-3-<(S)-(5-oxo-2-pyrrolidinyl)carbonyl>-thiazolidine-4-carboxylate 

Relevant articles and documents

Industrialized scale preparation method for pidotimod

The invention discloses an industrialized scale preparation method for pidotimod, and belongs to the technical field of medicine synthesis. The industrialized scale preparation method comprises the following steps of performing ring closure and esterification on L-cysteine, so as to obtain L-thiazolidine-carboxylic ester; then, condensing with L-pyroglutamic acid under the action of a condensing agent; then, performing ester hydrolysis, and crystallizing, so as to obtain a product meeting the medicinal standard. The industrialized scale preparation method has the advantages that the intermediate, such as L-thiazolidine-carboxylic ester hydrochloride, is not separated, the water is removed by a co-boiling method in the condensing reaction process, and the separating and drying steps of theintermediate are omitted; compared with other preparation methods, the technology is optimized, so as to shorten the large-scale production time, improve the yield rate, and reduce the production cost; the operability in the scale production of the pidotimod is realized.

Synthesis and preliminary pharmacological evaluation of pidotimod, its enantiomer, diastereomers and carboxamido derivatives

A new compound with a peptide-like structure, (R)-3-[(S)-(5-oxo-2-pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, its enantiomer, diastereomers and carboxamido derivatives were synthesized and tested for immunostimulant activity. Synthesis, preliminary, pharmacological data and structure-activity relationship are reported. (R)-3-[1(S)-(5-Oxo-2-pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid (1b, Pidotimod, PGT/1A, CAS 121808-62-6) was selected for further research.